|
|
|
| Utility of the Self-assembling Peptides as Novel Drug Formulations |
| SHAO Ming-xiang1,2, GONG Min1, TANG Li-da1,2 |
1. State Key Laboratory of Drug Delivery Technology and Pharmaceutics, Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;
2. Pharmacology, Tianjin Medical University, Tianjin 300080, China |
|
|
|
Abstract Self-assembled peptides possess distinct structural characterizations, inducing the formation of a stable supermolecule with a cavity. This central cavity was employed as drug carrier in last decade. The wide range utilities of self-assembled peptides covered the improved bioavailability, drug targeting release, cytotoxic alleviation, cell penetration activity and so on. There are two kinds of self-assembled peptide generally. One is based on the spatial structure of the peptide, and the other one is based on peptide amphiphile. Amphiphilic peptide has four rationally designed chemical entities. By reasonable controlling the chemical structure, amphiphilic peptides can self-assemble into a variety of nanostructures, such as nanofiber, nanotube, nanoparticles and hydrogel. It is highlighted a kind of peptide that is cellular penetration peptide(CPP). The mechanism of supermolecule formation and drug loading procedures was summarized. The remarkable functions of self-assembled peptides spread a prosperous scene in drug controlled release and drug sustained release.
|
|
Received: 06 May 2013
Published: 25 August 2013
|
|
|
|
|
[1] Lipinski C A. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods, 2000,44:235-249.
[2] Stella V J,Nti-Addae K W. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev, 2007,59:677-694.
[3] Allen T M,Cullis P R. Drug delivery systems: entering the mainstream. Science, 2004,303:1818-1822.
[4] Tang Y,Heaysman C L,Willis S,et al. Physical hydrogels with self-assembled nanostructures as drug delivery systems. Expert Opin Drug Deliv, 2011,8:1141-1159.
[5] Reches M,Gazit E. Molecular self-assembly of peptide nanostructures: mechanism of association and potential uses. Current Nanoscience, 2006,2:105-111.
[6] Gummel J,Sztucki M,Narayanan T,et al. Concentration dependent pathways in spontaneous self-assembly of unilamellar vesicles. Soft Matter, 2011,7:5731-5738.
[7] Fu I W,Markegard C B,Chu B K,et al. The role of electrostatics and temperature on morphological transitions of hydrogel nanostructures self-assembled by peptide amphiphiles via molecular dynamics simulations. Adv Healthc Mater, 2013,doi: 10.1002/adhm.201200400.
[8] Tang J,Yao J,Shi J,et al. Synthesis, characterization, drug-loading capacity and safety of novel pH-independent amphiphilic amino acid copolymer micelles. Pharmazie, 2012,67:756-764.
[9] 许小丁,陈昌盛,陈荆晓,等. 多肽分子自组装. 中国科学, 2011,41(2):221-238. Xu X D, Cheng C S, Chen J X, et al. Molecular self-assembly of peptide. Scientia Sinica Chimica, 2011,41(2):221-238.
[10] Cui H,Webber M J,Stupp S I. Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials. Biopolymers, 2010,94:1-18.
[11] Hartgerink J D,Beniash E,Stupp S I. Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials. Proc Natl Acad Sci U S A, 2002,99:5133-5138.
[12] Velichko Y S,Stupp S I, Cruz M O. Molecular simulation study of peptide amphiphile self-assembly. J Phys Chem B, 2008,112:2326-2334.
[13] Cui H,Muraoka T,Cheetham A G,et al. Self-assembly of giant peptide nanobelts. Nano Lett, 2009,9:945-951.
[14] Webber M J,Kessler J A,Stupp S I. Emerging peptide nanomedicine to regenerate tissues and organs. J Intern Med, 2010,267:71-88.
[15] Sasso L,Vedarethinam I,Emneus J,et al. Self-assembled diphenylalanine nanowires for cellular studies and sensor applications. J Nanosci Nanotechnol, 2012,12:3077-3083.
[16] Jaime C L,Bake S W. Self-assembled peptide nanostructures for biomedical applications: advantages and challenges. Biomaterials Science and Engineering, 2011,25:115-138.
[17] Tarek M,Maigret B,Chipot C. Molecular dynamics investigation of an oriented cyclic peptide nanotube in DMPC bilayers. Biophys J, 2003,85:2287-2298.
[18] Yu T,Lee O S,Schatz G C. Steered molecular dynamics studies of the potential of mean force for peptide amphiphile self-assembly into cylindrical nanofibers. J Phys Chem A, 2013,DOI: 10.1021/jp401508w.
[19] Jana N R. Shape effect in nanoparticle self-assembly. Angew Chem Int Ed Engl, 2004,43:1536-1540.
[20] Kurzawa L,Pellerano M,Morris M C. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells. Biochim Biophys Acta, 2010,1798:2274-2285.
[21] Eum W S,Kim D W,Hwang I K,et al. In vivo protein transduction: biologically active intact pep-1-superoxide dismutase fusion protein efficiently protects against ischemic insult. Free Radic Biol Med, 2004,37:1656-1669.
[22] Morris M C,Gros E,Aldrian-Herrada G,et al. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res, 2007,35:e49.
[23] Rittner K,Benavente A,Bompard-Sorlet A,et al. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther, 2002,5:104-114.
[24] Zhang X X,Eden H S,Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release, 2012,159:2-13.
[25] Konate K,Crombez L,Deshayes S,et al. Insight into the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery. Biochemistry, 2010,49:3393-3402.
[26] Crombez L,Divita G. A non-covalent peptide-based strategy for siRNA delivery. Methods Mol Biol, 2011,683:349-360.
[27] Deshayes S,Konate K,Rydstrom A,et al. Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines. Small, 2012,8:2184-2188.
[28] Rydstrom A,Deshayes S,Konate K,et al. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS One, 2011,6:e25924.
[29] Deshayes S,Konate K,Aldrian G,et al. Structural polymorphism of non-covalent peptide-based delivery systems: highway to cellular uptake. Biochim Biophys Acta, 2010,1798:2304-2314.
[30] Crowet J M,Lins L,Deshayes S,et al. Modeling of non-covalent complexes of the cell-penetrating peptide CADY and its siRNA cargo. Biochim Biophys Acta, 2013,1828:499-509.
[31] Cihlar T,Ray A S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res, 2010,85:39-58.
[32] Agopian A,Gros E,Aldrian-Herrada G,et al. A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. J Biol Chem, 2009,284:254-264.
[33] Morris M C,Depollier J,Mery J,et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol, 2001,19:1173-1176.
[34] Yao H J,Ju R J,Wang X X,et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials, 2011,32:3285-3302.
[35] Utreja P,Jain S,Tiwary A K. Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation. Drug Deliv, 2012,19:11-20.
[36] O'Connor T L,Kossoff E. Delayed seizure associated with paclitaxel-cremophorel in a patient with early-stage breast cancer. Pharmacotherapy, 2009,29:993-996.
[37] Rivkin I,Cohen K,Koffler J,et al. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials, 2010,31:7106-7114.
[38] Li S,Byrne B,Welsh J,et al. Self-assembled poly(butadiene)-b-poly(ethylene oxide) polymersomes as paclitaxel carriers. Biotechnol Prog, 2007,23:278-285.
[39] Van S,Das S K,Wang X,et al. Synthesis, characterization, and biological evaluation of poly(L-gamma-glutamyl-glutamine)-paclitaxel nanoconjugate. Int J Nanomedicine, 2010,5:825-837.
[40] Yokoi H,Kinoshita T,Zhang S. Dynamic reassembly of peptide RADA16 nanofiber scaffold. Proc Natl Acad Sci U S A, 2005,102:8414-8419.
[41] Liu J,Zhang L,Yang Z,et al. Controlled release of paclitaxel from a self-assembling peptide hydrogel formed in situ and antitumor study in vitro. Int J Nanomedicine, 2011,6:2143-2153.
[42] Li Y,Xu W,Tang L,et al. A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo. Peptides, 2011,32:1408-1414.
[43] Zheng X,Li Y,Li X,et al. Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes. Diabetes Res Clin Pract, 2011,93:410-420.
[44] Ruttimann E B,Arnold M,Geary N,et al. GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. Physiol Behav, 2010,100:291-296.
[45] 林娟,周庆翰,赵晓军. 荧光光谱对自组装多肽作为药物载体的初步研究. 光谱学与光谱分析, 2009,29(10):2792-2797. Lin J, Zhou Q H, Zhao X J. Study on the designed self-assembling peptide as potential drug carrier by fluorescence spectra. Spectroscopy and Spectral Analysis, 2009,29(10):2792-2797.
[46] Alexander J,Dainiak N,Berger H J,et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med, 1979,300:278-283.
[47] Von Hoff D D,Layard M W,Basa P,et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 1979,91:710-717.
[48] Li Y,Zheng X,Cao Z,et al. Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin. Int J Pharm, 2012,434:209-214.
[49] Veronese F M,Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today, 2005,10:1451-1458.
[50] Veronese F M,Schiavon O,Pasut G,et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem, 2005,16:775-784.
[51] Chari R V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res, 2008,41:98-107.
[52] Batrakova E V. Reversal of multidrug resistance by PEG-b-PLA polymeric micelles loaded with paclitaxel. Nanomedicine (Lond), 2011,6:1493-1494.
[53] Batrakova E V. Overcoming multidrug resistance using silica nanoparticles PEG-b-PLA polymeric micelles loaded with doxorubicin. Nanomedicine (Lond), 2011,6:1492-1493.
[54] Gou M,Shi H,Guo G,et al. Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles. Nanotechnology, 2011,22:095102.
[55] Gou M,Zheng L,Peng X,et al. Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int J Pharm, 2009,375:170-176.
[56] Gou M,Zheng X,Men K,et al. Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. J Phys Chem B, 2009,113:12928-12933.
[57] Qu W,Chen W H,Kuang Y,et al. Avidin-biotin interaction mediated peptide assemblies as efficient gene delivery vectors for cancer therapy. Mol Pharm, 2013,10:261-269. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
